PolyPid (PolyPid) Total Current Assets : $15.09 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is PolyPid Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. PolyPid's total current assets for the quarter that ended in Mar. 2024 was $15.09 Mil.

PolyPid Total Current Assets Historical Data

The historical data trend for PolyPid's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPid Total Current Assets Chart

PolyPid Annual Data

Trend

Dec12

Dec13

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

27.40

47.20

34.81

14.19

6.07

PolyPid Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															20.59	15.75	11.12	6.07	15.09

PolyPid Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

PolyPid's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	5.309	+	0	+	0	+	0.758
	=	6.07

PolyPid's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	14.456	+	0	+	0	+	0.637
	=	15.09

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

PolyPid (NAS:PYPD) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

PolyPid's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	14.456	-	18.25	+	0.75 * 0	+	0.5 * 0
=	-3.79

PolyPid Total Current Assets Related Terms

Thank you for viewing the detailed overview of PolyPid's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

PolyPid (PolyPid) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PolyPid Ltd (NAS:PYPD) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Hasivim Street, P.O Box 7126, Petach Tikva, ISR, 495376

Website

https://www.polypid.com

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, and Bacyssio are trademarks of the company. The company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.